MULLER.BO · BSE
MULLER & PHIPPS (INDIA) LTD.
₹206.4
-4.99% (-₹10.85)
Prev. close
₹217.25
Volume
123
As of
15 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About MULLER & PHIPPS (INDIA) LTD.
Muller & Phipps (India) Limited markets and distributes over the counter medical preparation and home care products in India. The company sells medicated dental cream, gel, and gum astringent products under the Cavisan brand; skincare products under the Cavidine and Nixoderm brand name; cosmetics and toiletries, medicated preparations, and food products. It markets its products through a network of chemists, general stores, provisional/kirana stores, and supermarkets. The company was incorporated in 1917 and is headquartered in Mumbai, India. The Muller & Phipps (India) Limited is a subsidiary of Development Holding Asia Ltd.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. P. V. Mohan
Headquarters
Mumbai
Website
mulphico.swayantra.comExchange
View on BSE ↗Key stats
Market cap
₹12.90 Cr
EPS (TTM)
₹-10.09
Beta (1Y · daily vs NIFTY 50)
0.35
Beta (5Y · monthly vs NIFTY 50)
-0.50
Shares float
1.36 L
EPS · quarter ended Jun 2026
₹1.83
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3.98 Cr | ₹3.67 Cr | ₹3.91 Cr | ₹4.14 Cr | ₹5.92 Cr | ₹5.63 Cr | |
| EBITDA | ₹51.90 L | ₹54.90 L | ₹30.27 L | ₹79.77 L | ₹-68.96 L | ₹4.16 L |
| ₹1.73 Cr | ₹43.50 L | ₹21.23 L | ₹72.81 L | ₹-75.69 L | ₹-4.75 L | |
| Diluted EPS | ₹27.63 | ₹6.96 | ₹3.4 | ₹11.65 | ₹-12.11 | ₹-0.76 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹4.98 Cr | ₹5.26 Cr | ₹5.72 Cr | ₹5.90 Cr | |
| — | — | ₹1.04 Cr | ₹77.06 L | ₹82.34 L | ₹75.12 L | |
| Stockholders' equity | — | — | ₹-2.02 Cr | ₹-1.30 Cr | ₹-2.08 Cr | ₹-2.08 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹20.53 L | ₹72.46 L | ₹-41.74 L | ₹11.90 L | |
| Investing cash flow | — | — | ₹-5,000 | ₹-1.68 L | ₹-63,000 | ₹0 |
| — | — | ₹-33.97 L | ₹-31.76 L | ₹4.58 L | ₹-10.99 L | |
| Capital expenditure | — | ₹-13,000 | ₹-5,000 | ₹-1.68 L | ₹-63,000 | — |
| End cash position | — | — | ₹11.16 L | ₹50.18 L | ₹12.39 L | ₹13.30 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| MULLER & PHIPPS (INDIA) LTD. | ₹12.90 Cr | ₹206.4 | — | — | — | — | -4.8% | -17.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Muller & Phipps (India) consolidated net profit declines 84.29% in the June 2026 quarter
Business Standard · 1 month ago